Novo Nordisk Golden Ticket program-Webinar

The Novo Nordisk x Biolabs partnership in Europe initiative supports life science entrepreneurs.

In this webinar, gain insights from a selected crowd of innovators in the field of Type 2 Diabetes, Obesity and Cardiovascular diseases, and learn more about the Golden Ticket opportunity.

Agenda

1 PM - Welcome & Webinar Agenda - Ann-Kristin Mueller, Site Director Biolabs Heidelberg and Christophe Tallec, Site Director Hôtel-Dieu.
1.05 PM - Welcome words - Daniel Brunicardi Timmermann, VP Innovation Outreach, Global Drug Discovery at Novo Nordisk
1.10 PM - Discovering the next generation of medicines for cardiometabolic disease: The scientific focus of Novo Nordisk - William Haynes, Scientific CVP, Novo Nordisk
1.30 PM - Fire-side chat with resident: Christophe Tarabout - CEO Vitropep, 2023 Novo Nordisk Golden Ticket winner
1.40 PM - Golden Ticket campaign and Q&A
Wrap-up

What is a Golden Ticket?

Golden Tickets award the best startups with a year's worth of lab and innovation ecosystem access (a wet-lab bench, a desk, a membership, a strong community of peers, investors, and other pharmaceutical partners). You will be able join either our Germany’s strong life science and biotech hub in Heidelberg at Biolabs Heidelberg, or the Biolabs Paris Hôtel-Dieu at the heart of the care journey of AP-HP, world-renowned university hospital center, with a European dimension. Learn more about Biolabs premier co-working spaces for life science startups on the respective site links.

About Novo Nordisk

Novo Nordisk is a leading pharmaceutical company in cardiometabolic disease R&D, with more than 100 years of experience in discovering, creating and sponsoring innovation to solve healthcare challenges for patients with diabetes, obesity, cardiovascular disease, NASH, chronic kidney disease, and rare blood and endocrine disorders.

What is Novo Nordisk searching for?

Start-ups working on novel drug targets and medicines in cardiometabolic disease, in particular:

Type 2 Diabetes

Efficacy beyond blood glucose lowering
Restoring insulin resistance
Regeneration & disease-modification
Obesity

Enhancing energy expenditure
Modulating hedonic eating behavior
Modulating counter-regulatory mechanisms
Cardiovascular disease

Atherosclerosis beyond LDL/TG lowering
Precision-medicine for heart failure
Disease-modification for HF & cardiomyopathy
Resistant hypertension & unstable angina
Drug discovery & enabling technology

Drug discovery & enabling technology in the above stated therapeutic areas and additionally in MASH, chronic kidney disease and rare, non-malignant hematology.